Chagas CardiomyopathyNCT04239144
Sympathetic Denervation by Video-assisted Thoracoscopy in Control of Cardiac Arrhythmias in Patients With Chagas Disease
A study testing Bilateral sympathectomy and Catheter ablation in people with Chagas Cardiomyopathy and Ventricular Arrythmia, run by University of Sao Paulo General Hospital at 1 site in Brazil.
Trial summary
Ventricular tachycardia (VT) is the main cause of sudden death in patients with structural heart diseases. The use of ICD (implantable cardio-defibrillator) could prevent sudden death, however, the occurrence of repetitive shock decreases significantly the quality of life and could increase the mortality rate. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chagas Cardiomyopathy, Ventricular Arrythmia
- What is being tested?
- Bilateral sympathectomy and Catheter ablation
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 45 participants
- Where
- 1 siteBrazil
- Study dates
- 9 Nov 2018to 12 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with Chagas Disease Cardiomyopathy having an ICD
- At least four appropriate ICD therapies in the past six months, documented by device interrogation or medical records;
- Use of amiodarone and beta blockers in an optimized fashion;
- Life expectancy of more than one year
- Conditions for following the plan of clinical follow-up of the study.
Who cannot join
- Presence of an absolute contraindication to receive any of the possible treatments of the study;
- Pregnant Woman;
- Less than 18 years-old;
- Renal insufficiency with creatinine >2.5 mg/dL (221 umol/L);
- Mobile thrombus in the left ventricle;
- Left Ventricle Ejection fraction < 10%;
Show all 11Show fewer
- Unstable angina;
- Severe aortic stenosis
- Primary severe mitral insufficiency;
- New York Heart Association (NYHA) functional class IV;
- Previous cardiac surgery or scheduled.
Trial locations and contacts
1 site in 1 country.
Brazil1 site
Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
São Paulo, São Paulo, 05403-900
About this study
Official title: Role of Sympathetic Denervation by Video-assisted Thoracoscopy in Control of Cardiac Arrhythmias in Patients With Chagas Disease - Pilot Study Randomized Controlled Trial
Ventricular tachycardia (VT) is the main cause of sudden death in patients with structural heart diseases. The use of ICD (implantable cardio-defibrillator) could prevent sudden death, however, the occurrence of repetitive shock decreases significantly the quality of life and could increase the mortality rate. Chagas disease in our environment is the most common heart disease and often associated with the occurrence appropriate ICD therapies.
The chronic treatment of VT aims to prevent recurrences with the use of antiarrhythmic drugs and catheter ablation, but in many cases, these treatments are insufficient to control the VT. Cardiac Sympathetic Denervation by bilateral sympathectomy has been described as an alternative treatment of VT refractory to medical treatment and radiofrequency ablation, especially in patients with channelopathies. This treatment could have a role in patients with structural heart disease.
The objective of this study is to evaluate the efficacy of the bilateral sympathectomy in the reduction of ventricular tachycardia in patients with Chagas cardiomyopathy. In this pilot study, the investigators will select 45 patients with Chagas cardiomyopathy with ICD who presented at least four ICD therapies in the prior six months. These patients will be randomly assigned to three groups, 15 patients in medical therapy group, 15 in catheter ablation and 15 in bilateral sympathectomy.
Read the detailed description
OBJECTIVE
Primary
- Evaluate the efficacy of bilateral sympathectomy in the reduction of VT episodes in patients with Chagas cardiomyopathy.
Secondary
- To compare the efficacy of bilateral sympathectomy against VT ablation and against optimal medical therapy.
- To evaluate the density of ventricular premature beats 24-hour Holter and monitor the events recorded by the ICD and the impact of the treatment performed.
- To evaluate the length of the hospital stay according to the type of intervention.
- To evaluate the rate of clinical complications according to the type of intervention.
- To evaluate the impact of treatment on left ventricular function.
Follow up
Outcomes Assessment in six months and one year
- Recurrence rate of appropriate therapies;
- Density of ventricular ectopies;
- Complication rates per type of intervention;
- Number of in-hospital days per type of intervention;
- Assessment of LV function;
METHODS
This is a pilot, single-centre, open-label, randomized trial in patients with Chagas disease and multiple appropriate ICD therapies. This study consists of three groups: (1) medical treatment, (2) catheter ablation and (3) bilateral sympathectomy, being included 15 patients in each group.
Inclusion Criteria:
- Patients with Chagas Disease Cardiomyopathy having an ICD
- At least four appropriate ICD therapies in the past six months, documented by device interrogation or medical records;
- Use of amiodarone and beta blockers in an optimized fashion;
- Life expectancy of more than one year
- Conditions for following the plan of clinical follow-up of the study.
Exclusion criteria:
- Presence of an absolute contraindication to receive any of the possible treatments of the study;
- Pregnant Woman;
- Less than 18 years-old;
- Renal insufficiency with creatinine >2.5 mg/dL (221 umol/L);
- Mobile thrombus in the left ventricle;
- Left Ventricle Ejection fraction < 10%;
- Unstable angina;
- Severe aortic stenosis
- Primary severe mitral insufficiency;
- New York Heart Association (NYHA) functional class IV;
- Previous cardiac surgery or scheduled.
The patients will be recruited consecutively in the outpatient clinic of Cardiac Pacing Unit, or in outpatient clinic of Arrhythmias Clinical Unit or in the Emergency Clinical Unit.
Group 1 - Medical Treatment: patients allocated to this group will receive amiodarone reimpregnation, incremental dose of beta-blocker and if possible ICD reprogramming.
Group 2 - Catheter ablation: patients allocated to this group will undergo epicardial and endocardial catheter ablation with the use of an irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced, activation mapping will also be performed. The aim of the ablation is to eliminate the clinical VT additionally to substrate modification. The result of ablation will be defined as (1) complete success (all VTs non-inducible); (2) partial success (clinical VT non inducible, but other morphologies still inducible) and (3) failure (clinical VT still inducible).
Group 3 - Bilateral sympathectomy - bilateral sympathectomy will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consists of lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches. The cephalic portion of the stellate ganglion will be preserved to avoid Horner's syndrome and the electrocautery use will also be avoided for the same reason. Hemodynamic and echocardiographic behaviors will be continuously monitored during these surgical maneuvers. After the application, 10 ml of 0.25% bupivacaine solution will be injected along the site of the pleural dissection for postoperative analgesia. The lung will be reinflated under direct vision and a small tube will be inserted to remove the air through the upper incision, which will be removed at the end of the operation if possible. The two port sites will be closed primarily with absorbable stitches.
The study conformed to the principles outlined in the Declaration of Helsinki and was approved by the ethics committee and institutional review board of our hospital. All patients will provide written informed consent before randomization.
- Conditions
- Chagas Cardiomyopathy, Ventricular Arrythmia
- Being tested
- Bilateral sympathectomy, Catheter ablation
- Keywords
- Ventricular Tachycardia,, Chagas Disease, Catheter Ablation, Bilateral Sympathectomy, Cardiac Sympathetic Denervation
- Medical subject headings
- Chagas Cardiomyopathy, Tachycardia, Ventricular, Chagas Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bilateral sympathectomyProcedure or surgery
Also called Cardiac Sympathetic Denervation
Bilateral sympathectomy will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consisted of left lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches. The cephalic portion of the stellate ganglion was preserved to avoid Horner's syndrome and the electrocautery use was also avoided due to the same reason. The nerve was blocked using Ultracision device to avoid thermic lesion of the stellate ganglion. Hemodynamic and echocardiographic behaviors were continuously monitored during these surgical maneuvers.
Catheter ablationProcedure or surgery
Catheter ablation - patients allocated to this group will undergone epicardial and endocardial catheter ablation with the use of irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced activation mapping will also be performed. The aim of the ablation is to eliminate the clinical VT additionally to substrate modification. The result of ablation will be defined as (1) complete success; (2) partial success and (3) failure.
| Study group | Role | What they receive |
|---|---|---|
| Medical therapy group | No intervention | Arm 1 - 15 patients allocated to this group will receive conventional antiarrhythmic medical treatment according the guidelines with additional impregnation of amiodarone, incremental dose of beta-blocker and if possible ICD reprograming. |
| Catheter ablation | Active comparator | Intervention Arm 2 -15 patients allocated to this group will undergo epicardial and endocardial catheter ablation with the use of irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced, activation mapping will also be performed. The result of ablation will be defined as (1) complete success (all VTs non-inducible); (2) partial success (clinical VT non inducible, but other morphologies still inducible) and (3) failure (clinical VT still inducible). Receives: Procedure: Catheter ablation |
| Bilateral sympathectomy | Experimental | Interventional Arm 3 - 15 patients allocated to this group will undergo bilateral sympathectomy, which will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consists of lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches. The cephalic portion of the stellate ganglion will be preserved to avoid Horner's syndrome and the electrocautery use will also be avoided for the same reason. Hemodynamic and echocardiographic behaviors will be continuously monitored during these surgical maneuvers. Receives: Procedure: Bilateral sympathectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to Ventricular Tachycardia Recurrence
Compare the time to the first documented Ventricular Tachycardia episode between groups
Measured: 12 months
Burden of Ventricular Tachycardia Recurrence
Compare the number of Ventricular Tachycardia episodes between groups in 12 months
Measured: 12 months
Secondary outcomes (7)
Ventricular Tachycardia Recurrence Following Sympathectomy Compared to Catheter Ablation.
Time to first VT episode after sympathectomy compared to Catheter ablation
Measured: 12 months
Mortality and Transplant Rate
To compare between groups the number of patients who died or received a cardiac transplant at the end of the follow-up
Measured: 12 months
Ventricular Ectopic Beats Density
To evaluate the density of ventricular premature beats in the 24-hour Holter in the follow-up, for each group.
Measured: 12 months
Length of Hospital Stay
Compare the number of in-hospital days according to the type of intervention.
Measured: 12 months
Rate of Complications Following Intervention
Compare the rate of clinical complications according to the type of intervention.
Measured: 12 months
Impact on Left Ventricular Ejection Fraction
To evaluate the variations of the Left Ventricular Ejection Fraction in each group.
Measured: 12 months
Autonomic Measures
To compare the RR variability measures in the 24h-Holter between groups
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jan 2020
- Study start9 Nov 2018
- Primary completion18 Nov 2025
- Study completion12 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chagas CardiomyopathyStudies of the same condition, open and under way.
- More trials run by University of Sao Paulo General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- In this pilot study, the investigators will select 45 patients with Chagas cardiomyopathy with ICD who presented at least four ICD therapies in the prior six months. These patients will be randomly assigned to three groups, 15 patients in medical therapy group, 15 in catheter ablation and 15 in bilateral sympathectomy. The objective of this study is to evaluate the efficacy of the bilateral sympathectomy in the reduction of ventricular tachycardia in patients with Chagas cardiomyopathy.
- Masking
- None (open label)
- Enrolment
- 45 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Sao Paulo General Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Biosense Webster, Inc.
- Responsible party
- Principal investigator, Paulo Manuel Pêgo Fernandes, University of Sao Paulo General Hospital
- Investigators
- Paulo M Pego Fernandes, MD, PhD, Principal investigator, Instituto do Coração Faculdade de Medicina da USP - (INCOR-FMUSP)Rodrigo M Kulchetscki, MD, Principal investigator, Instituto do Coração Faculdade de Medicina da USP - (INCOR-FMUSP)Maurício I Scanavacca, MD, PhD, Study director, Instituto do Coração Faculdade de Medicina da USP - (INCOR-FMUSP)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04239144
- Sponsor's protocol ID
- 49701215.2.0000.0068
- Status last verified
- Feb 2026
- First submitted
- 23 Jan 2019
- Last updated
- 10 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Deidentified data will be shared with other investigators upon request.
Study at a glance
From the registry record, last updated by the sponsor on 10 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Role of Sympathetic Denervation by Video-assisted Thoracoscopy in Control of Cardiac Arrhythmias in Patients With Chagas Disease - Pilot Study Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT04239144
- Acronym / sponsor ID
- 49701215.2.0000.0068
- Conditions
- Chagas Cardiomyopathy, Ventricular Arrythmia
- Keywords
- Ventricular Tachycardia,, Chagas Disease, Catheter Ablation, Bilateral Sympathectomy, Cardiac Sympathetic Denervation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 45 participants (actual)
- Lead sponsor
- University of Sao Paulo General HospitalUniversity, hospital or other
- Collaborators
- Biosense Webster, Inc.
- Study start
- 9 Nov 2018 (actual)
- Primary completion
- 18 Nov 2025 (actual)
- Study completion
- 12 Dec 2025 (actual)
- First posted
- 23 Jan 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Ventricular tachycardia (VT) is the main cause of sudden death in patients with structural heart diseases. The use of ICD (implantable cardio-defibrillator) could prevent sudden death, however, the occurrence of repetitive shock decreases significantly the quality of life and could increase the mortality rate. Chagas disease in our environment is the most common heart disease and often associated with the occurrence appropriate ICD therapies.
The chronic treatment of VT aims to prevent recurrences with the use of antiarrhythmic drugs and catheter ablation, but in many cases, these treatments are insufficient to control the VT. Cardiac Sympathetic Denervation by bilateral sympathectomy has been described as an alternative treatment of VT refractory to medical treatment and radiofrequency ablation, especially in patients with channelopathies. This treatment could have a role in patients with structural heart disease.
The objective of this study is to evaluate the efficacy of the bilateral sympathectomy in the reduction of ventricular tachycardia in patients with Chagas cardiomyopathy. In this pilot study, the investigators will select 45 patients with Chagas cardiomyopathy with ICD who presented at least four ICD therapies in the prior six months. These patients will be randomly assigned to three groups, 15 patients in medical therapy group, 15 in catheter ablation and 15 in bilateral sympathectomy.
Detailed description
OBJECTIVE
Primary
- Evaluate the efficacy of bilateral sympathectomy in the reduction of VT episodes in patients with Chagas cardiomyopathy.
Secondary
- To compare the efficacy of bilateral sympathectomy against VT ablation and against optimal medical therapy.
- To evaluate the density of ventricular premature beats 24-hour Holter and monitor the events recorded by the ICD and the impact of the treatment performed.
- To evaluate the length of the hospital stay according to the type of intervention.
- To evaluate the rate of clinical complications according to the type of intervention.
- To evaluate the impact of treatment on left ventricular function.
Follow up
Outcomes Assessment in six months and one year
- Recurrence rate of appropriate therapies;
- Density of ventricular ectopies;
- Complication rates per type of intervention;
- Number of in-hospital days per type of intervention;
- Assessment of LV function;
METHODS
This is a pilot, single-centre, open-label, randomized trial in patients with Chagas disease and multiple appropriate ICD therapies. This study consists of three groups: (1) medical treatment, (2) catheter ablation and (3) bilateral sympathectomy, being included 15 patients in each group.
Inclusion Criteria:
- Patients with Chagas Disease Cardiomyopathy having an ICD
- At least four appropriate ICD therapies in the past six months, documented by device interrogation or medical records;
- Use of amiodarone and beta blockers in an optimized fashion;
- Life expectancy of more than one year
- Conditions for following the plan of clinical follow-up of the study.
Exclusion criteria:
- Presence of an absolute contraindication to receive any of the possible treatments of the study;
- Pregnant Woman;
- Less than 18 years-old;
- Renal insufficiency with creatinine >2.5 mg/dL (221 umol/L);
- Mobile thrombus in the left ventricle;
- Left Ventricle Ejection fraction < 10%;
- Unstable angina;
- Severe aortic stenosis
- Primary severe mitral insufficiency;
- New York Heart Association (NYHA) functional class IV;
- Previous cardiac surgery or scheduled.
The patients will be recruited consecutively in the outpatient clinic of Cardiac Pacing Unit, or in outpatient clinic of Arrhythmias Clinical Unit or in the Emergency Clinical Unit.
Group 1 - Medical Treatment: patients allocated to this group will receive amiodarone reimpregnation, incremental dose of beta-blocker and if possible ICD reprogramming.
Group 2 - Catheter ablation: patients allocated to this group will undergo epicardial and endocardial catheter ablation with the use of an irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced, activation mapping will also be performed. The aim of the ablation is to eliminate the clinical VT additionally to substrate modification. The result of ablation will be defined as (1) complete success (all VTs non-inducible); (2) partial success (clinical VT non inducible, but other morphologies still inducible) and (3) failure (clinical VT still inducible).
Group 3 - Bilateral sympathectomy - bilateral sympathectomy will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consists of lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches. The cephalic portion of the stellate ganglion will be preserved to avoid Horner's syndrome and the electrocautery use will also be avoided for the same reason. Hemodynamic and echocardiographic behaviors will be continuously monitored during these surgical maneuvers. After the application, 10 ml of 0.25% bupivacaine solution will be injected along the site of the pleural dissection for postoperative analgesia. The lung will be reinflated under direct vision and a small tube will be inserted to remove the air through the upper incision, which will be removed at the end of the operation if possible. The two port sites will be closed primarily with absorbable stitches.
The study conformed to the principles outlined in the Declaration of Helsinki and was approved by the ethics committee and institutional review board of our hospital. All patients will provide written informed consent before randomization.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- In this pilot study, the investigators will select 45 patients with Chagas cardiomyopathy with ICD who presented at least four ICD therapies in the prior six months. These patients will be randomly assigned to three groups, 15 patients in medical therapy group, 15 in catheter ablation and 15 in bilateral sympathectomy. The objective of this study is to evaluate the efficacy of the bilateral sympathectomy in the reduction of ventricular tachycardia in patients with Chagas cardiomyopathy.
| Arm | Type | Receives |
|---|---|---|
| Medical therapy group | No intervention | –Arm 1 - 15 patients allocated to this group will receive conventional antiarrhythmic medical treatment according the guidelines with additional impregnation of amiodarone, incremental dose of beta-blocker and if possible ICD reprograming. |
| Catheter ablation | Active comparator | Procedure: Catheter ablationIntervention Arm 2 -15 patients allocated to this group will undergo epicardial and endocardial catheter ablation with the use of irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced, activation mapping will also be performed. The result of ablation will be defined as (1) complete success (all VTs non-inducible); (2) partial success (clinical VT non inducible, but other morphologies still inducible) and (3) failure (clinical VT still inducible). |
| Bilateral sympathectomy | Experimental | Procedure: Bilateral sympathectomyInterventional Arm 3 - 15 patients allocated to this group will undergo bilateral sympathectomy, which will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consists of lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches. The cephalic portion of the stellate ganglion will be preserved to avoid Horner's syndrome and the electrocautery use will also be avoided for the same reason. Hemodynamic and echocardiographic behaviors will be continuously monitored during these surgical maneuvers. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patients with Chagas Disease Cardiomyopathy having an ICD
- At least four appropriate ICD therapies in the past six months, documented by device interrogation or medical records;
- Use of amiodarone and beta blockers in an optimized fashion;
- Life expectancy of more than one year
- Conditions for following the plan of clinical follow-up of the study.
Key exclusion criteria (11 listed)
- Presence of an absolute contraindication to receive any of the possible treatments of the study;
- Pregnant Woman;
- Less than 18 years-old;
- Renal insufficiency with creatinine >2.5 mg/dL (221 umol/L);
- Mobile thrombus in the left ventricle;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bilateral sympathectomyAlso: Cardiac Sympathetic DenervationBilateral sympathectomy will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consisted of left lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches. The cephalic portion of the stellate ganglion was preserved to avoid Horner's syndrome and the electrocautery use was also avoided due to the same reason. The nerve was blocked using Ultracision device to avoid thermic lesion of the stellate ganglion. Hemodynamic and echocardiographic behaviors were continuously monitored during these surgical maneuvers. | Procedure or surgery | Bilateral sympathectomy |
| Catheter ablationCatheter ablation - patients allocated to this group will undergone epicardial and endocardial catheter ablation with the use of irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced activation mapping will also be performed. The aim of the ablation is to eliminate the clinical VT additionally to substrate modification. The result of ablation will be defined as (1) complete success; (2) partial success and (3) failure. | Procedure or surgery | Catheter ablation |
Primary outcome
Time to Ventricular Tachycardia Recurrence
Time frame: 12 months
Compare the time to the first documented Ventricular Tachycardia episode between groups
Burden of Ventricular Tachycardia Recurrence
Time frame: 12 months
Compare the number of Ventricular Tachycardia episodes between groups in 12 months
7 secondary outcomes
Ventricular Tachycardia Recurrence Following Sympathectomy Compared to Catheter Ablation.
Time frame: 12 months
Mortality and Transplant Rate
Time frame: 12 months
Ventricular Ectopic Beats Density
Time frame: 12 months
Length of Hospital Stay
Time frame: 12 months
Rate of Complications Following Intervention
Time frame: 12 months
Impact on Left Ventricular Ejection Fraction
Time frame: 12 months
Autonomic Measures
Time frame: 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Feb 2026.
- Individual participant dataSharing planned: Yes. Deidentified data will be shared with other investigators upon request.
Related trials for Chagas Cardiomyopathy
Recruiting
Cardiac Contractility Modulation in Chagas Heart Disease
Chagas Cardiomyopathy, Heart Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Paulo M Pego Fernandes, MD, PhD principal investigator
Instituto do Coração Faculdade de Medicina da USP - (INCOR-FMUSP)
Rodrigo M Kulchetscki, MD principal investigator
Instituto do Coração Faculdade de Medicina da USP - (INCOR-FMUSP)
Maurício I Scanavacca, MD, PhD study director
Instituto do Coração Faculdade de Medicina da USP - (INCOR-FMUSP)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Bilateral sympathectomy and Catheter ablation in people with Chagas Cardiomyopathy and Ventricular Arrythmia, run by University of Sao Paulo General Hospital at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to Ventricular Tachycardia Recurrence (time frame: 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2026.